{
    "root": "b73fd0be-3cb6-4284-817b-a4fec41a3a6a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "ACCOLATE"
    },
    "value": "20250321",
    "ingredients": [
        {
            "name": "ZAFIRLUKAST",
            "code": "XZ629S5L50"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "accolate indicated prophylaxis chronic treatment asthma adults children 5 years age older .",
    "contraindications": "food reduce bioavailability zafirlukast , accolate taken least 1 hour 2 hours meals . adults children 12 years age older recommended dose accolate adults children 12 years older 20 mg twice daily . pediatric patients 5 11 years age recommended dose accolate children 5 11 years age 10 mg twice daily . elderly patients based cross-study comparisons , clearance zafirlukast reduced elderly patients ( 65 years age older ) , cmax auc approximately twice younger adults . trials , dose 20 mg twice daily associated increase overall incidence events withdrawals events elderly patients . patients hepatic impairment accolate contraindicated patients hepatic impairment including hepatic cirrhosis ( ) . clearance zafirlukast reduced patients stable alcoholic cirrhosis cmax auc approximately 50 60 % greater normal adults . accolate evaluated patients hepatitis long-term patients cirrhosis . patients renal impairment adjustment required patients renal impairment .",
    "warningsAndPrecautions": "accolate 10 mg tablets , ( ndc 6464380-177-01 ) white , round , biconvex , film-coated tablets debossed `` p `` one side `` 10 `` , supplied opaque hdpe bottles 60 tablets . accolate 20 mg tablets , ( ndc 64380-178-01 ) white , round , biconvex , film-coated tablets debossed `` p `` one side `` 20 `` , supplied opaque hdpe bottles 60 tablets . store controlled room temperature , 20 25\u00b0c ( 68 77\u00b0f ) [ usp ] . protect light moisture . dispense original air-tight container .",
    "adverseReactions": "accolate contraindicated patients hypersensitive zafirlukast inactive ingredients . accolate contraindicated patients hepatic impairment including hepatic cirrhosis .",
    "indications_original": "ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.",
    "contraindications_original": "Because food can reduce the bioavailability of zafirlukast, ACCOLATE should be taken at least 1 hour before or 2 hours after meals.\n                  \n                     Adults and Children 12 years of age and older\n                  \n                  The recommended dose of ACCOLATE in adults and children 12 years and older is 20 mg twice daily.\n                  \n                     Pediatric Patients 5 through 11 years of age \n                  \n                  The recommended dose of ACCOLATE in children 5 through 11 years of age is 10 mg twice daily.\n                  \n                     Elderly Patients\n                  \n                  Based on cross-study comparisons, the clearance of zafirlukast is reduced in elderly patients (65 years of age and older), such that Cmax and AUC are approximately twice those of younger adults.\u00a0 In clinical trials, a dose of 20 mg twice daily was not associated with an increase in the overall incidence of adverse events or withdrawals because of adverse events in elderly patients.\n                  \n                     Patients with Hepatic Impairment\n                  \n                  ACCOLATE is contraindicated in patients with hepatic impairment including hepatic cirrhosis (see Contraindications). The clearance of zafirlukast is reduced in patients with stable alcoholic cirrhosis such that the Cmax and AUC are approximately 50 to 60% greater than those of normal adults.\u00a0 ACCOLATE has not been evaluated in patients with hepatitis or in long-term studies of patients with cirrhosis.\n                  \n                     Patients with Renal Impairment\n                  \n                  Dosage adjustment is not required for patients with renal impairment.",
    "warningsAndPrecautions_original": "ACCOLATE 10 mg Tablets, (NDC 6464380-177-01) white, round, biconvex, film-coated tablets debossed with \"P\" on one side and \"10\" on the other, are supplied in opaque HDPE bottles of 60 tablets.\n                  \n                     ACCOLATE 20 mg Tablets, (NDC 64380-178-01) white, round, biconvex, film-coated tablets debossed with \"P\" on one side and \"20\" on the other, are supplied in opaque HDPE bottles of 60 tablets.\n                  Store at controlled room temperature, 20 to 25\u00b0C (68 to 77\u00b0F) [see USP]. Protect from light and moisture. Dispense in the original air-tight container.",
    "adverseReactions_original": "ACCOLATE is contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients.\n                  ACCOLATE is contraindicated in patients with hepatic impairment including hepatic cirrhosis."
}